Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs
Bioorganic and Medicinal Chemistry, Volume 14, No. 24, Year 2006
Notification
URL copied to clipboard!
Description
In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of mammalian DHFR activity. Molecular modeling studies were used to assess the fit of these compounds within the active site of human DHFR. The synthesized compounds were evaluated for their ability to inhibit mammalian DHFR in vitro and for their antitumor activity in a standard in vitro tissue culture assay panel. Compounds 28, 30, and 31 were the most active DHFR inhibitors with IC50 values of 0.5, 0.4, and 0.4 μM, respectively. The most active antitumor agents in this study were compounds 19, 31, 41, and 47 with median growth inhibitory concentrations (GI50) of 20.1, 23.5, 26.7, and 9.1 μM, respectively. Of this series of compounds, only compound 31 combined antitumor potency with potent DHFR inhibition; the other active antitumor compounds (19, 41, and 47) all had DHFR IC50 values above 15 μM, suggesting that they might exert their antitumor potency through some other mode of action. Alternatively, the compounds could differ significantly in uptake or concentration within mammalian cells. © 2006 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Alrashood, Sara T.
Saudi Arabia, Riyadh
College of Pharmacy
Aboldahab, Ihsan A.
Saudi Arabia, Riyadh
College of Pharmacy
Nagi, Mahmoud N.
Saudi Arabia, Riyadh
College of Pharmacy
Abou-Zeid, Laila A.
Saudi Arabia, Riyadh
College of Pharmacy
Abdel-Aziz, Alaa A.M.
Saudi Arabia, Riyadh
College of Pharmacy
Abdel-Hamide, Sami G.
Saudi Arabia, Riyadh
College of Pharmacy
Youssef, Khairia M.
Saudi Arabia, Riyadh
College of Pharmacy
Al-Obaid, Abdulrahman Mohammad
Saudi Arabia, Riyadh
College of Pharmacy
El-Subbagh, Hussein I.
Saudi Arabia, Riyadh
College of Pharmacy
Statistics
Citations: 176
Authors: 9
Affiliations: 1
Identifiers
Doi:
10.1016/j.bmc.2006.08.030
ISSN:
09680896